NEUPATH HEALTH INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.17 CAD | +3.03% |
|
+6.25% | -8.11% |
| 03-15 | NeuPath Health Narrows Q4 Loss, Revenue Rises | MT |
| 03-15 | NeuPath Health Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | 62.65M 45.9M | Sales 2023 | 66.1M 48.42M | Capitalization | 10.41M 7.63M |
|---|---|---|---|---|---|
| Net income 2022 | -4M -2.93M | Net income 2023 | - 0 | EV / Sales 2022 | 0.35 x |
| Net Debt 2022 | 12.65M 9.27M | Net Debt 2023 | 8.94M 6.55M | EV / Sales 2023 | 0.29 x |
| P/E ratio 2022 |
-2.09
x | P/E ratio 2023 |
-95.3
x | Employees | 156 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99.12% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.03% | ||
| 1 week | +6.25% | ||
| Current month | +3.03% | ||
| 1 month | +3.03% | ||
| 3 months | -2.86% | ||
| 6 months | +6.25% | ||
| Current year | -8.11% |
1 week
0.17
0.17
1 month
0.140.19
Current year
0.140.20
1 year
0.120.25
3 years
0.080.77
5 years
0.081.43
10 years
0.081.43
| Managers | Title | Age | Since |
|---|---|---|---|
Joseph Walewicz
CEO | Chief Executive Officer | 55 | 20-06-24 |
Danish Baig
DFI | Director of Finance/CFO | - | 23-04-30 |
Jeff Zygouras
DFI | Director of Finance/CFO | - | 18-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Joseph Walewicz
CEO | Chief Executive Officer | 55 | 20-06-24 |
Daniel Chicoine
CHM | Chairman | 70 | 20-06-24 |
Sasha Cucuz
BRD | Director/Board Member | 46 | 20-06-24 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 0.17 | +3.03% | 36,500 |
| 24-04-23 | 0.165 | 0.00% | 17,000 |
| 24-04-22 | 0.165 | +3.13% | 25,000 |
Delayed Quote Toronto S.E., April 24, 2024 at 03:57 pm
More quotes
NeuPath Health Inc. operates a network of healthcare clinics and related businesses focused on improved access to care and outcomes for patients by leveraging treatments and delivering patient-centered multidisciplinary care. The Company operates a network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. It provides workplace health services and independent medical assessments to employers and disability insurers through a national network of healthcare providers, as well as contract research services to pharmaceutical and biotechnology companies. The Company's health care providers cover a range of specialties, which include physiatrists, neurologists, anesthesiologists, general practitioners with specialized training in chronic pain, as well as medication management physicians, athletic therapists, and nurses.
Calendar
2024-05-22
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.17
CAD
Average target price
0.5
CAD
Spread / Average Target
+194.12%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -8.11% | 6.99M | |
| -14.17% | 84.68B | |
| +15.20% | 81.12B | |
| +11.62% | 29.59B | |
| -9.49% | 16.73B | |
| -1.46% | 16.36B | |
| -31.58% | 11.77B | |
| +1.98% | 11.72B | |
| +30.82% | 11.71B | |
| -0.47% | 11.66B |
- Stock Market
- Equities
- NPTH Stock
